跳至主要内容
临床试验/2024-515259-40-00
2024-515259-40-00招募中3 期

Contrast-enhanced ultrasound for sentinel node detection in patients with melanoma, breast cancer or head & neck cancer (N24CUS)

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting1 个研究点 分布在 1 个国家目标入组 91 人开始时间: 2024年12月9日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
招募中
入组人数
91
试验地点
1
主要终点
sensitivity and specificity of the CEUS SN localization method

研究概览

简要总结

To assess the sensitivity and specificity of CEUS for intra-operative SN localization compared to the gold standard (99mTc nanocolloid).

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Aged 18 years or older
  • Patient has been diagnosed with cancer in the skin (melanoma), breast or head & neck (including melanoma of head and neck area)
  • In case of a melanoma: it should be located in the limbs or head and neck area
  • Scheduled for a surgical SN procedure at the NKI-AvL
  • Patient provides written informed consent

排除标准

  • Any known clinically significant acute hypersensitivity reaction to the study medication, such as eggs or egg products
  • Other contra-indications for Sonazoid contrast agent, including arteriovenous cardiac or pulmonary shunt, serious coronary arterial disease and serious pulmonary disease

结局指标

主要结局

sensitivity and specificity of the CEUS SN localization method

sensitivity and specificity of the CEUS SN localization method

次要结局

  • time required to localize the SNs using CEUS in minutes
  • usability of the CEUS system using a system-usability-score (SUS)
  • sensitivity and specificity of using CEUS to predict if SNs are malignant

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Dr. Q.R.J.G. Tummers

Scientific

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

研究点 (1)

Loading locations...

相似试验